Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 79,351 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Chronic Subdural Hematoma
Interventions: Numen SILK coil embolization system; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 98 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Walnut Creek, California • New York, New York

Conditions: Head and Neck Cancer, Non Small Cell Lung Cancer
Interventions: Erlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Constipation, Pain
Interventions: Naloxegol, Placebo; Drug
Lead sponsor: Hospice of Henderson County, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: New York, New York • Flat Rock, North Carolina • Cleveland, Ohio

Conditions: Stress, Depression
Interventions: Jauntly, Online stress management information; Behavioral
Lead sponsor: Oregon Center for Applied Science, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 298 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Allergy;Food, Allergy to Shrimp, Allergy to Cashew Nut (Disorder)
Interventions: Cashew or Shrimp Oral Immunotherapy; Drug
Lead sponsor: Sayantani B. Sindher; Other
Eligibility: 7 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Small Cell Lung Cancer
Interventions: ADI-PEG 20 (Arginine deiminase pegylated); Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: New York, New York • Durham, North Carolina

Conditions: Asthma
Interventions: CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 134
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: BRCA-Gist; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia • Richmond, Virginia

Conditions: Colorectal Polyps
Interventions: evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Leukemia
Interventions: Cyclophosphamide, Methotrexate, Prednisone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 68
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 48 more

Conditions: Head and Neck Cancer
Interventions: Docetaxel, OSI-774, Cisplatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions: Bionic Pancreas (BP) with Aspart or Lispro, Bionic Pancreas with Fiasp (BPFiasp), Usual Care (UC), BP Guidance Insulin Dosing; Combination Product · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 6 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 16
States / cities: Orange, California • San Diego, California • Stanford, California + 13 more

Conditions: Jaw, Edentulous, Partially
Interventions: OsseoSpeed™; Device
Lead sponsor: Dentsply Sirona Implants and Consumables; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Iowa City, Iowa • San Antonio, Texas

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: ALT-801, Gemcitabine; Biological · Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Birmingham, Alabama • Sacramento, California • Orlando, Florida + 2 more

Conditions: Medication Adherence
Interventions: PatientToc use in pharmacies; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years and older
Enrollment: 1,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Breast Cancer
Interventions: Amcenestrant (SAR439859), Letrozole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • Fort Wayne, Indiana + 3 more

Conditions: Cutaneous Lichen Planus
Interventions: Placebo, GIA632; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Birmingham, Alabama • Fountain Valley, California • Hollywood, Florida + 16 more

Conditions: Plaque Psoriasis
Interventions: roflumilast cream 0.3%, Zoryve, Placebo; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography; Procedure · Drug · Dietary Supplement
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis
Interventions: REGN3500, REGN3500-Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Gastric Adenocarcinoma
Interventions: Gleevec, Taxotere; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus
Interventions: Structured Group Exercise; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Migraine
Interventions: Fremanezumab-Vfrm, BLAfit®, Saline; Drug · Device · Other
Lead sponsor: Manhattan Beach Orthodontics; Other
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions: LY2605541, Insulin glargine; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

The CHALLENGER Registry

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

Mobile-Web Emotion Self-management Tool

Food Allergen OIT for Shrimp and Cashew

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

Comparison of Two Types of Biopsy Forceps for Obtaining Cold Biopsy Polypectomy for Small Sessile Colorectal Polyps Less Than 6 mm in Diameter

Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

The Insulin-Only Bionic Pancreas Pivotal Trial

Study on OsseoSpeed™ Implants Replacing 2-5 Teeth in the Posterior Upper Jaw, Restored With Provisional Teeth Attached 6-7 Weeks Later

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Evaluation of PatientToc in Community Pharmacies

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study

Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar